CommercialCoverageMedium impact
08.00.72l, Alglucosidase alfa (e.g., Lumizyme®), Avalglucosidase alfa-ngpt (Nexviazyme® ), Cipaglucosidase alfa-atga (Pombiliti™ )
Independence Blue Cross·Neurology, Pediatrics, Endocrinology·Pharmacy
Effective date
Nov 26, 2025
We identified it
Jun 19, 2026
Summary
This is a reissued policy update for enzyme replacement therapies including Lumizyme, Nexviazyme, and Pombiliti used to treat Pompe disease. The policy was both reissued and made effective on 11/26/2025, indicating an immediate update to coverage or prior authorization requirements for these specialized medications.
Action Required
Immediately: Billing team should access the full policy at the provided URL to review specific changes to coverage criteria, prior authorization requirements, or billing guidelines for alglucosidase alfa, avalglucosidase alfa-ngpt, and cipaglucosidase alfa-atga. Update any standing prior authorization protocols and inform providers treating Pompe disease patients of potential changes to approval processes.